Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study.

Lemmer JH Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al.

J Thorac Cardiovasc Surg. 1994 Feb;107(2):543-51; discussion 551-3.

PMID:
7508070
2.

A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting.

Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P.

Circulation. 1995 Oct 15;92(8):2236-44.

3.

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A.

J Thorac Cardiovasc Surg. 1998 Nov;116(5):716-30.

4.

Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy.

Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A.

Eur J Cardiothorac Surg. 1995;9(4):206-10.

PMID:
7541637
5.

Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood.

Havel M, Grabenwöger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E.

J Thorac Cardiovasc Surg. 1994 Mar;107(3):807-10.

PMID:
7510351
6.

The impact of aprotinin on coronary artery bypass graft patency.

Laub GW, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB.

Chest. 1994 Nov;106(5):1370-5.

PMID:
7525162
7.

Recombinant aprotinin in coronary artery bypass graft operations.

Green D, Sanders J, Eiken M, Wong CA, Frederiksen J, Joob A, Palmer A, Trowbridge A, Woodruff B, Moerch M, et al.

J Thorac Cardiovasc Surg. 1995 Oct;110(4 Pt 1):963-70.

8.

Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations.

Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ.

J Thorac Cardiovasc Surg. 1994 Feb;107(2):554-61.

PMID:
7508071
9.

The efficacy and safety of aprotinin use in cardiac surgery.

Rich JB.

Ann Thorac Surg. 1998 Nov;66(5 Suppl):S6-11; discussion S25-8. Review.

PMID:
9869434
10.

Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.

Cosgrove DM 3rd, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD.

Ann Thorac Surg. 1992 Dec;54(6):1031-6; discussion 1036-8.

PMID:
1280411
11.

Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization.

Kalangos A, Tayyareci G, Prêtre R, Di Dio P, Sezerman O.

Eur J Cardiothorac Surg. 1994;8(12):651-6.

PMID:
7535064
12.

Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement.

Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB.

J Bone Joint Surg Am. 2000 May;82(5):675-84.

PMID:
10819278
13.

Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery.

Lass M, Simic O, Ostermeyer J.

Cardiovasc Surg. 1997 Dec;5(6):604-7.

PMID:
9423946
15.

Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens.

Lemmer JH Jr, Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, Copeland JG 3rd, Ochsner JL, Daily PO, Whitten CW, Noon GP, Maddi R.

Ann Thorac Surg. 1996 Dec;62(6):1659-67; discussion 1667-8.

PMID:
8957369
16.

Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency.

Bidstrup BP, Underwood SR, Sapsford RN, Streets EM.

J Thorac Cardiovasc Surg. 1993 Jan;105(1):147-52; discussion 153.

PMID:
7678314
17.

Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.

Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.

Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b.

PMID:
18931201
18.

Effects of minimal-dose aprotinin on coronary artery bypass grafting.

Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S.

J Thorac Cardiovasc Surg. 1997 Aug;114(2):261-9.

19.

[Effect of aprotinin on bleeding during and graft patency after coronary artery bypass grafting].

Minohara S, Asada K, Kondo K, Tatsumi T, Hasegawa S, Sawada Y, Morimoto T, Matsuyama N, Sasaki S.

Nihon Kyobu Geka Gakkai Zasshi. 1997 Jun;45(6):821-4. Japanese.

PMID:
9217377
20.

Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study.

van der Meer J, Hillege HL, Ascoop CA, Dunselman PH, Mulder BJ, van Ommen GV, Pfisterer M, van Gilst WH, Lie KI.

Thromb Haemost. 1996 Jan;75(1):1-3.

PMID:
8713770

Supplemental Content

Support Center